Products
Linavonkibart Biosimilar Monoclonal Antibody (TGF-β1) for Research
Cat No.: GMP-Bios-INN-1258
Anti-TGFB1 therapeutic antibody (Pre-made Linavonkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Linavonkibart (development code SRK-181) is a humanized monoclonal antibody targeting TGF-beta1 (TGFB1). It is developed by Scholar Rock for solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1258-1mg | 1mg | 3090 |
| GMP-Bios-INN-1258-10mg | 10mg | |
| GMP-Bios-INN-1258-100mg | 100mg | |
| GMP-Bios-INN-1258-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Linavonkibart biosimilar, Whole mAb, Anti-TGFB1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody |
| INN Name | Linavonkibart |
| Target | TGFB1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Scholar Rock |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
